Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02215


Performance of self-care recommendations is key to the successful treatment of diabetes. However, many patients have difficulty adhering to diabetes self-care recommendations. Recent results from our own studies and others have identified specific barriers to diabetes self-care. To evaluate the efficacy of a diabetes educator-led group intervention, the Breaking Down Barriers Program, that addresses barriers and therefore leads to improved adherence to diabetes self-care recommendations, we will randomize 222 (111 type 1 and 111 type 2) diabetes patients to one of three conditions: 1) the Breaking Down Barriers Program, 2) a cholesterol attention control condition, or 3) a 'usual care' control condition. We hypothesize that those assigned to the Breaking Down Barriers group will improve self-care behaviors and glycemic control more than those in the two control groups. We will follow study subjects for one year to determine whether their self-care behaviors and glycemic control improved and if the improvement was maintained over time.


Inclusion Criteria: For Patients With Type 1 Diabetes - Aged 18-65 - Presence of type 1 diabetes mellitus. - 2-25 year duration. For Patients With Type 2 Diabetes - Aged 25-65 years - presence of type 2 diabetes mellitus. - 2 years since initial diagnosis. Exclusion Criteria: - Renal disease, microalbumin >300 ug/mg) - Severe peripheral diabetic neuropathy and/or severe peripheral vascular disease - Symptomatic severe autonomic neuropathy who may be at risk when increasing activity levels. - Women who are currently pregnant - proliferative diabetic retinopathy based on dilated eye examination within one year of study entry. Patients whose eye disease is successfully treated will be included. - HbA1c levels less than 7.0% (normal range 4.0 - 6.0%). - HbA1c levels greater than 14.0% - patients who underwent intensive insulin treatment within one year - a history of severe, unstable myocardial infarction, congestive heart failure or other severe cardiac disease, severe hypertension (systolic more than 160 mmHg or diastolic 90 mmHg) who may be at risk when mildly increasing physical activity - a DSMIV diagnosis of eating disorders including anorexia nervosa, bulimia, and severe weight-related insulin omission. - Patients with recent diagnosis (past 6 months) of bipolar disorder, schizophrenia, mental retardation, organic mental disorder, and alcohol or drug abuse - Patients whose diabetes diagnosed cannot be clearly classified as type 1 or type 2.



Primary Contact:

Principal Investigator
Katie Weinger, EdD
Joslin Diabetes Center/Harvard Medical School

Backup Contact:


Location Contact:

Boston, Massachusetts 02215
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.